576 lines
45 KiB
HTML
576 lines
45 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="zh-CN">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<title>干细胞概念股深度研究报告</title>
|
||
|
||
<!-- Frameworks & Libraries -->
|
||
<script src="https://cdn.tailwindcss.com"></script>
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.10.2/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||
<script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
|
||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||
|
||
<!-- Custom Styles & Fonts -->
|
||
<link rel="preconnect" href="https://fonts.googleapis.com">
|
||
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
|
||
<link href="https://fonts.googleapis.com/css2?family=Noto+Sans+SC:wght@300;400;500;700&family=Orbitron:wght@400;700&display=swap" rel="stylesheet">
|
||
|
||
<style>
|
||
/* Define custom theme and styles */
|
||
:root {
|
||
--glow-color-primary: 0, 255, 255;
|
||
--glow-color-secondary: 255, 0, 255;
|
||
}
|
||
|
||
html {
|
||
scroll-behavior: smooth;
|
||
}
|
||
|
||
body {
|
||
font-family: 'Noto Sans SC', sans-serif;
|
||
background-color: #020418;
|
||
background-image:
|
||
radial-gradient(circle at 15% 15%, rgba(var(--glow-color-primary), 0.15) 0%, transparent 40%),
|
||
radial-gradient(circle at 85% 75%, rgba(var(--glow-color-secondary), 0.12) 0%, transparent 40%),
|
||
url('data:image/svg+xml,%3Csvg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 80 80" width="80" height="80"%3E%3Crect fill="%23020418" width="80" height="80"%3E%3C/rect%3E%3Cg fill-opacity="0.1"%3E%3Ccircle fill="%2300ffff" cx="40" cy="40" r="60"%3E%3C/circle%3E%3Ccircle fill="%2300f6ff" cx="40" cy="40" r="59"%3E%3C/circle%3E%3Ccircle fill="%2300edff" cx="40" cy="40" r="58"%3E%3C/circle%3E%3Ccircle fill="%2300e3ff" cx="40" cy="40" r="57"%3E%3C/circle%3E%3Ccircle fill="%2300daff" cx="40" cy="40" r="56"%3E%3C/circle%3E%3Ccircle fill="%2300d1ff" cx="40" cy="40" r="55"%3E%3C/circle%3E%3Ccircle fill="%2300c8ff" cx="40" cy="40" r="54"%3E%3C/circle%3E%3Ccircle fill="%2300bfff" cx="40" cy="40" r="53"%3E%3C/circle%3E%3Ccircle fill="%2300b6ff" cx="40" cy="40" r="52"%3E%3C/circle%3E%3Ccircle fill="%2300adff" cx="40" cy="40" r="51"%3E%3C/circle%3E%3Ccircle fill="%2300a5ff" cx="40" cy="40" r="50"%3E%3C/circle%3E%3Ccircle fill="%23009cff" cx="40" cy="40" r="49"%3E%3C/circle%3E%3Ccircle fill="%230094ff" cx="40" cy="40" r="48"%3E%3C/circle%3E%3Ccircle fill="%23008cff" cx="40" cy="40" r="47"%3E%3C/circle%3E%3Ccircle fill="%230084ff" cx="40" cy="40" r="46"%3E%3C/circle%3E%3Ccircle fill="%23007cff" cx="40" cy="40" r="45"%3E%3C/circle%3E%3Ccircle fill="%230075ff" cx="40" cy="40" r="44"%3E%3C/circle%3E%3Ccircle fill="%23006dff" cx="40" cy="40" r="43"%3E%3C/circle%3E%3Ccircle fill="%230066ff" cx="40" cy="40" r="42"%3E%3C/circle%3E%3Ccircle fill="%23005fff" cx="40" cy="40" r="41"%3E%3C/circle%3E%3Ccircle fill="%230058ff" cx="40" cy="40" r="40"%3E%3C/circle%3E%3Ccircle fill="%230051ff" cx="40" cy="40" r="39"%3E%3C/circle%3E%3Ccircle fill="%23004aff" cx="40" cy="40" r="38"%3E%3C/circle%3E%3Ccircle fill="%230044ff" cx="40" cy="40" r="37"%3E%3C/circle%3E%3Ccircle fill="%23003dff" cx="40" cy="40" r="36"%3E%3C/circle%3E%3Ccircle fill="%230037ff" cx="40" cy="40" r="35"%3E%3C/circle%3E%3Ccircle fill="%230031ff" cx="40" cy="40" r="34"%3E%3C/circle%3E%3Ccircle fill="%23002aff" cx="40" cy="40" r="33"%3E%3C/circle%3E%3Ccircle fill="%230024ff" cx="40" cy="40" r="32"%3E%3C/circle%3E%3Ccircle fill="%23001eff" cx="40" cy="40" r="31"%3E%3C/circle%3E%3Ccircle fill="%230018ff" cx="40" cy="40" r="30"%3E%3C/circle%3E%3Ccircle fill="%230012ff" cx="40" cy="40" r="29"%3E%3C/circle%3E%3Ccircle fill="%230d0cff" cx="40" cy="40" r="28"%3E%3C/circle%3E%3Ccircle fill="%231e0aff" cx="40" cy="40" r="27"%3E%3C/circle%3E%3Ccircle fill="%232b08ff" cx="40" cy="40" r="26"%3E%3C/circle%3E%3Ccircle fill="%233606ff" cx="40" cy="40" r="25"%3E%3C/circle%3E%3Ccircle fill="%234004ff" cx="40" cy="40" r="24"%3E%3C/circle%3E%3Ccircle fill="%234902ff" cx="40" cy="40" r="23"%3E%3C/circle%3E%3Ccircle fill="%235100ff" cx="40" cy="40" r="22"%3E%3C/circle%3E%3Ccircle fill="%235800ff" cx="40" cy="40" r="21"%3E%3C/circle%3E%3Ccircle fill="%235f00ff" cx="40" cy="40" r="20"%3E%3C/circle%3E%3Ccircle fill="%236600ff" cx="40" cy="40" r="19"%3E%3C/circle%3E%3Ccircle fill="%236c00ff" cx="40" cy="40" r="18"%3E%3C/circle%3E%3Ccircle fill="%237200ff" cx="40" cy="40" r="17"%3E%3C/circle%3E%3Ccircle fill="%237800ff" cx="40" cy="40" r="16"%3E%3C/circle%3E%3Ccircle fill="%237e00ff" cx="40" cy="40" r="15"%3E%3C/circle%3E%3Ccircle fill="%238400ff" cx="40" cy="40" r="14"%3E%3C/circle%3E%3Ccircle fill="%238900ff" cx="40" cy="40" r="13"%3E%3C/circle%3E%3Ccircle fill="%238e00ff" cx="40" cy="40" r="12"%3E%3C/circle%3E%3Ccircle fill="%239300ff" cx="40" cy="40" r="11"%3E%3C/circle%3E%3Ccircle fill="%239800ff" cx="40" cy="40" r="10"%3E%3C/circle%3E%3Ccircle fill="%239c00ff" cx="40" cy="40" r="9"%3E%3C/circle%3E%3Ccircle fill="%23a100ff" cx="40" cy="40" r="8"%3E%3C/circle%3E%3Ccircle fill="%23a500ff" cx="40" cy="40" r="7"%3E%3C/circle%3E%3Ccircle fill="%23a900ff" cx="40" cy="40" r="6"%3E%3C/circle%3E%3Ccircle fill="%23ad00ff" cx="40" cy="40" r="5"%3E%3C/circle%3E%3Ccircle fill="%23b100ff" cx="40" cy="40" r="4"%3E%3C/circle%3E%3Ccircle fill="%23b500ff" cx="40" cy="40" r="3"%3E%3C/circle%3E%3Ccircle fill="%23b800ff" cx="40" cy="40" r="2"%3E%3C/circle%3E%3Ccircle fill="%23bc00ff" cx="40" cy="40" r="1"%3E%3C/circle%3E%3C/g%3E%3C/svg%3E');
|
||
background-attachment: fixed;
|
||
}
|
||
|
||
.orbitron {
|
||
font-family: 'Orbitron', sans-serif;
|
||
}
|
||
|
||
.glass-card {
|
||
background: rgba(16, 18, 42, 0.4);
|
||
backdrop-filter: blur(20px);
|
||
-webkit-backdrop-filter: blur(20px);
|
||
border: 1px solid rgba(0, 255, 255, 0.15);
|
||
transition: all 0.3s ease;
|
||
}
|
||
|
||
.glass-card:hover {
|
||
border-color: rgba(0, 255, 255, 0.4);
|
||
box-shadow: 0 0 25px rgba(var(--glow-color-primary), 0.2);
|
||
}
|
||
|
||
.glow-text-primary {
|
||
text-shadow: 0 0 8px rgba(var(--glow-color-primary), 0.7);
|
||
}
|
||
|
||
.glow-text-secondary {
|
||
text-shadow: 0 0 8px rgba(var(--glow-color-secondary), 0.7);
|
||
}
|
||
|
||
.bento-grid {
|
||
display: grid;
|
||
grid-template-columns: repeat(12, 1fr);
|
||
gap: 1.5rem;
|
||
}
|
||
|
||
.bento-item {
|
||
border-radius: 1.5rem;
|
||
padding: 1.5rem;
|
||
overflow: hidden;
|
||
position: relative;
|
||
}
|
||
|
||
.bento-item-title {
|
||
font-family: 'Orbitron', sans-serif;
|
||
font-size: 1.25rem;
|
||
margin-bottom: 1rem;
|
||
color: #c9d1d9;
|
||
display: flex;
|
||
align-items: center;
|
||
}
|
||
|
||
.bento-item-title::before {
|
||
content: '';
|
||
display: inline-block;
|
||
width: 4px;
|
||
height: 20px;
|
||
background-color: #00ffff;
|
||
margin-right: 0.75rem;
|
||
box-shadow: 0 0 8px rgba(var(--glow-color-primary), 0.7);
|
||
border-radius: 2px;
|
||
}
|
||
|
||
.table thead th {
|
||
background-color: rgba(0, 255, 255, 0.05);
|
||
color: #00ffff;
|
||
}
|
||
|
||
.table tbody tr {
|
||
border-bottom: 1px solid rgba(0, 255, 255, 0.1);
|
||
transition: background-color 0.2s ease;
|
||
}
|
||
|
||
.table tbody tr:hover {
|
||
background-color: rgba(0, 255, 255, 0.08);
|
||
}
|
||
|
||
.tab {
|
||
transition: all 0.3s ease;
|
||
}
|
||
|
||
.tab-active {
|
||
color: #00ffff !important;
|
||
border-color: #00ffff !important;
|
||
box-shadow: 0 0 10px rgba(var(--glow-color-primary), 0.5);
|
||
}
|
||
|
||
/* Custom scrollbar */
|
||
::-webkit-scrollbar {
|
||
width: 8px;
|
||
}
|
||
::-webkit-scrollbar-track {
|
||
background: rgba(16, 18, 42, 0.5);
|
||
}
|
||
::-webkit-scrollbar-thumb {
|
||
background: rgba(0, 255, 255, 0.3);
|
||
border-radius: 4px;
|
||
}
|
||
::-webkit-scrollbar-thumb:hover {
|
||
background: rgba(0, 255, 255, 0.5);
|
||
}
|
||
</style>
|
||
</head>
|
||
<body class="text-gray-300 min-h-screen">
|
||
|
||
<div class="container mx-auto p-4 md:p-8">
|
||
<!-- Header -->
|
||
<header class="text-center mb-12 animate-fade-in-down">
|
||
<h1 class="orbitron text-4xl md:text-6xl font-bold text-cyan-300 glow-text-primary mb-4">
|
||
干细胞概念股
|
||
</h1>
|
||
<p class="text-xl md:text-2xl text-fuchsia-400 glow-text-secondary orbitron">深度研究报告</p>
|
||
<div class="mt-4 text-xs text-gray-500">
|
||
由 北京价值前沿科技有限公司 AI投研agent：“价小前投研” 进行投研呈现<br>本报告为AI合成数据，投资需谨慎
|
||
</div>
|
||
</header>
|
||
|
||
<main class="space-y-8">
|
||
<!-- Bento Grid Layout -->
|
||
<div class="bento-grid">
|
||
|
||
<!-- 0. 概念事件 -->
|
||
<div class="bento-item glass-card col-span-12 lg:col-span-8">
|
||
<h2 class="bento-item-title">概念事件：产业化拐点已至</h2>
|
||
<div class="space-y-4 text-gray-400 text-sm md:text-base leading-relaxed">
|
||
<p>干细胞概念近期受到市场高度关注，其核心驱动力源于一系列政策、技术及商业化的里程碑事件，标志着行业从漫长的研发投入期开始迈向商业化应用的拐点。</p>
|
||
<ul class="list-none space-y-3 pl-2">
|
||
<li class="flex items-start">
|
||
<svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5 text-cyan-400 mr-3 mt-1 flex-shrink-0" fill="none" viewBox="0 0 24 24" stroke="currentColor"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z" /></svg>
|
||
<div><strong class="text-cyan-400">【全球验证】2024年底：</strong>美国FDA批准首款“现货型”间充质干细胞（MSC）疗法Ryoncil，用于治疗GVHD，极大提振了全球行业信心。</div>
|
||
</li>
|
||
<li class="flex items-start">
|
||
<svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5 text-cyan-400 mr-3 mt-1 flex-shrink-0" fill="none" viewBox="0 0 24 24" stroke="currentColor"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z" /></svg>
|
||
<div><strong class="text-cyan-400">【国内破冰】2025年1月2日：</strong>国家药监局附条件批准铂生卓越生物的艾米迈托赛注射液上市，成为中国首款干细胞治疗药品，标志着中国干细胞疗法商业化元年正式开启。</div>
|
||
</li>
|
||
<li class="flex items-start">
|
||
<svg xmlns="http://www.w3.org/2000/svg" class="h-5 w-5 text-cyan-400 mr-3 mt-1 flex-shrink-0" fill="none" viewBox="0 0 24 24" stroke="currentColor"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z" /></svg>
|
||
<div><strong class="text-cyan-400">【技术突破信号】2024-2025年：</strong>上海长征医院利用iPSC分化胰岛细胞实现2型糖尿病临床“治愈”个例，展示了下一代干细胞技术的巨大潜力，引发市场广泛关注。</div>
|
||
</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 1. 核心观点摘要 -->
|
||
<div class="bento-item glass-card col-span-12 lg:col-span-4">
|
||
<h2 class="bento-item-title">核心观点摘要</h2>
|
||
<p class="text-gray-400 text-sm md:text-base leading-relaxed">
|
||
干细胞产业在政策破冰与技术验证的双重驱动下，正经历从主题炒作向基本面驱动的<strong class="text-fuchsia-400">产业化初期过渡</strong>的关键拐点。未来，该概念的潜力将由<strong class="text-cyan-400">核心在研管线的临床数据</strong>和<strong class="text-cyan-400">商业化产品的放量速度</strong>共同决定，具备高壁垒、大适应症管线的头部企业有望享受行业爆发的红利。
|
||
</p>
|
||
</div>
|
||
|
||
<!-- 2. 概念的核心逻辑与市场认知分析 -->
|
||
<div class="bento-item glass-card col-span-12">
|
||
<h2 class="bento-item-title">概念的核心逻辑与市场认知分析</h2>
|
||
<div class="grid grid-cols-1 md:grid-cols-3 gap-6">
|
||
<div class="p-4 rounded-xl border border-cyan-500/20 bg-cyan-500/5">
|
||
<h3 class="font-bold text-lg text-cyan-300 mb-2">核心驱动力</h3>
|
||
<ul class="list-disc list-inside space-y-2 text-gray-400 text-sm">
|
||
<li><strong class="text-gray-300">政策法规确定性：</strong>CDE系列指导文件和首药获批，扫清最大政策障碍，打通“药品”路径。</li>
|
||
<li><strong class="text-gray-300">技术成熟与验证：</strong>以MSC为代表的技术路线成熟，占国内临床试验80%以上，首批药物获批完成从“概念”到“药物”的关键一跃。</li>
|
||
<li><strong class="text-gray-300">商业化路径打通：</strong>首药获批和试点项目（如博鳌乐城定价3-15万/疗程）意味着产品可定价、销售、产生收入。</li>
|
||
</ul>
|
||
</div>
|
||
<div class="p-4 rounded-xl border border-fuchsia-500/20 bg-fuchsia-500/5">
|
||
<h3 class="font-bold text-lg text-fuchsia-300 mb-2">市场热度与情绪</h3>
|
||
<p class="text-gray-400 text-sm">市场情绪<strong class="text-gray-300">高度乐观</strong>，新闻端的“首款获批”、“治愈糖尿病”迅速点燃热情。券商研报和路演密集覆盖，机构积极布局。市场普遍认为行业正处0到1的爆发前夜，对标CAR-T疗法发展路径。</p>
|
||
</div>
|
||
<div class="p-4 rounded-xl border border-gray-500/20 bg-gray-500/5">
|
||
<h3 class="font-bold text-lg text-gray-300 mb-2">预期差分析</h3>
|
||
<ul class="list-disc list-inside space-y-2 text-gray-400 text-sm">
|
||
<li><strong class="text-gray-300">新旧业务模式：</strong>市场高估了传统“细胞存储”业务的支撑能力，低估了新药研发对资金的消耗。</li>
|
||
<li><strong class="text-gray-300">临床进度快慢：</strong>市场对短期商业化过于乐观，忽略了临床试验漫长周期（如九芝堂脑卒中预计2029年完成）。</li>
|
||
<li><strong class="text-gray-300">竞争格局寡众：</strong>焦点集中于少数上市公司，忽略了汉氏联合、西比曼等众多非上市实力玩家。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 3. 关键催化剂与未来发展路径 -->
|
||
<div class="bento-item glass-card col-span-12">
|
||
<h2 class="bento-item-title">关键催化剂与未来发展路径</h2>
|
||
<div class="grid grid-cols-1 md:grid-cols-2 gap-6">
|
||
<div>
|
||
<h3 class="font-semibold text-cyan-300 mb-3">近期催化剂 (未来3-6个月)</h3>
|
||
<div class="space-y-3">
|
||
<div class="p-3 bg-slate-800/50 rounded-lg border-l-4 border-cyan-400">
|
||
<p class="font-semibold text-gray-200">核心临床数据读出</p>
|
||
<p class="text-xs text-gray-400">
|
||
中源协和：牙髓干细胞治疗牙周炎II期数据 (预计2025 H1)<br>
|
||
九芝堂：aPAP适应症2a期数据 (即将公布)
|
||
</p>
|
||
</div>
|
||
<div class="p-3 bg-slate-800/50 rounded-lg border-l-4 border-cyan-400">
|
||
<p class="font-semibold text-gray-200">第二梯队产品申报</p>
|
||
<p class="text-xs text-gray-400">进入III期临床的管线（如克罗恩病、膝骨关节炎）的上市申请受理。</p>
|
||
</div>
|
||
<div class="p-3 bg-slate-800/50 rounded-lg border-l-4 border-cyan-400">
|
||
<p class="font-semibold text-gray-200">商业化定价与医保政策</p>
|
||
<p class="text-xs text-gray-400">艾米迈托赛注射液的最终定价、销售数据及医保动态。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div>
|
||
<h3 class="font-semibold text-fuchsia-300 mb-3">长期发展路径</h3>
|
||
<div class="space-y-3">
|
||
<div class="p-3 bg-slate-800/50 rounded-lg border-l-4 border-fuchsia-400">
|
||
<p class="font-semibold text-gray-200">适应症拓展 (由罕至常)</p>
|
||
<p class="text-xs text-gray-400">从GVHD等罕见病，逐步向膝骨关节炎、心衰、脑卒中等千万级患者的慢性病拓展。</p>
|
||
</div>
|
||
<div class="p-3 bg-slate-800/50 rounded-lg border-l-4 border-fuchsia-400">
|
||
<p class="font-semibold text-gray-200">技术迭代 (从MSC到iPSC)</p>
|
||
<p class="text-xs text-gray-400">iPSC技术在糖尿病等领域的突破，有望成为行业下一波浪潮。</p>
|
||
</div>
|
||
<div class="p-3 bg-slate-800/50 rounded-lg border-l-4 border-fuchsia-400">
|
||
<p class="font-semibold text-gray-200">产业链成熟 (从作坊到工厂)</p>
|
||
<p class="text-xs text-gray-400">上游培养基、设备及下游CDMO服务将迎来爆发式增长，推动成本下降。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 产业链图谱 & 市场规模 -->
|
||
<div class="bento-item glass-card col-span-12 lg:col-span-7">
|
||
<h2 class="bento-item-title">产业链图谱</h2>
|
||
<div class="relative p-4">
|
||
<div class="flex justify-between items-center text-center text-xs md:text-sm">
|
||
<div class="w-1/3 p-2 rounded-lg bg-cyan-900/30 border border-cyan-700">
|
||
<p class="font-bold text-cyan-300">上游</p>
|
||
<p class="text-gray-400">工具与服务层</p>
|
||
<p class="mt-2 text-gray-500">培养基、试剂、设备、CRO/CDMO</p>
|
||
</div>
|
||
<div class="text-2xl text-cyan-400 font-mono">>></div>
|
||
<div class="w-1/3 p-2 rounded-lg bg-indigo-900/30 border border-indigo-700">
|
||
<p class="font-bold text-indigo-300">中游</p>
|
||
<p class="text-gray-400">制备与存储层</p>
|
||
<p class="mt-2 text-gray-500">干细胞采集、制备、存储 (牌照壁垒)</p>
|
||
</div>
|
||
<div class="text-2xl text-fuchsia-400 font-mono">>></div>
|
||
<div class="w-1/3 p-2 rounded-lg bg-fuchsia-900/30 border border-fuchsia-700">
|
||
<p class="font-bold text-fuchsia-300">下游</p>
|
||
<p class="text-gray-400">应用与治疗层</p>
|
||
<p class="mt-2 text-gray-500">药物研发、临床试验、商业化销售</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="bento-item glass-card col-span-12 lg:col-span-5">
|
||
<h2 class="bento-item-title">市场规模预测</h2>
|
||
<div id="market-size-chart" style="width: 100%; height: 180px;"></div>
|
||
</div>
|
||
|
||
|
||
<!-- 4. 核心公司深度剖析 -->
|
||
<div class="bento-item glass-card col-span-12">
|
||
<h2 class="bento-item-title">核心玩家深度剖析</h2>
|
||
<div class="overflow-x-auto">
|
||
<table class="table table-sm">
|
||
<thead>
|
||
<tr>
|
||
<th>公司名称</th>
|
||
<th>核心逻辑</th>
|
||
<th>竞争优势</th>
|
||
<th>进展与催化剂</th>
|
||
<th>潜在风险</th>
|
||
<th class="text-center">纯粹度</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr class="hover">
|
||
<td class="font-bold text-white">中源协和 (600645)</td>
|
||
<td>存储现金牛 + 研发期权</td>
|
||
<td>国内布局最广、管线最丰富(6个临床阶段)</td>
|
||
<td class="text-cyan-300">牙周炎II期数据(2025 H1)</td>
|
||
<td>核心存储业务增长乏力，新药研发投入巨大</td>
|
||
<td class="text-center">中等</td>
|
||
</tr>
|
||
<tr class="hover">
|
||
<td class="font-bold text-white">九芝堂 (000989)</td>
|
||
<td>高潜力适应症 + 国资背景</td>
|
||
<td>聚焦脑卒中(百亿市场)，临床进度国内领先</td>
|
||
<td class="text-cyan-300">aPAP适应症2a期数据即将读出</td>
|
||
<td>研发管线相对集中，商业化周期长(预计2029)</td>
|
||
<td class="text-center">高</td>
|
||
</tr>
|
||
<tr class="hover">
|
||
<td class="font-bold text-white">天士力 (600535)</td>
|
||
<td>合作引进 + 自主研发</td>
|
||
<td>与全球MSC龙头Mesoblast深度合作，聚焦心衰</td>
|
||
<td class="text-cyan-300">引进产品在中国IND获批</td>
|
||
<td>合作方产品在美国III期数据未达主要终点</td>
|
||
<td class="text-center">中等</td>
|
||
</tr>
|
||
<tr class="hover">
|
||
<td class="font-bold text-white">我武生物 (300357)</td>
|
||
<td>主业稳健 + 第二增长曲线</td>
|
||
<td>主业现金流充裕，战略转型决心强，6年技术储备</td>
|
||
<td class="text-cyan-300">计划近期提交临床申请</td>
|
||
<td>尚处临床前，从0到1不确定性最大</td>
|
||
<td class="text-center">低(目前)</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
<blockquote class="mt-6 p-4 border-l-4 border-amber-500 bg-amber-900/20 text-amber-200 rounded-r-lg">
|
||
<p class="font-semibold">验证与证伪交叉点：</p>
|
||
<p class="text-sm">市场普遍看好中源协和“存储+研发”模式，但研报指出其“<strong class="text-white">近年干细胞存储业务增长乏力，存储份数明显下滑</strong>”。这一点构成了重要风险点，其“现金牛”业务对高昂研发费用的支撑能力需被重新评估。</p>
|
||
</blockquote>
|
||
</div>
|
||
|
||
<!-- 5. 潜在风险与挑战 & 6. 综合结论 -->
|
||
<div class="bento-item glass-card col-span-12 lg:col-span-6">
|
||
<h2 class="bento-item-title">潜在风险与挑战</h2>
|
||
<ul class="list-none space-y-2 text-gray-400 text-sm">
|
||
<li class="flex"><strong class="w-16 text-red-400 flex-shrink-0">技术风险:</strong><span>临床试验失败风险，长期安全性有效性待验证，iPSC致瘤性等。</span></li>
|
||
<li class="flex"><strong class="w-16 text-red-400 flex-shrink-0">商业风险:</strong><span>高昂定价(数十万)支付能力存疑，规模化生产与质控壁垒高。</span></li>
|
||
<li class="flex"><strong class="w-16 text-red-400 flex-shrink-0">政策风险:</strong><span>后续定价、医保准入、临床应用规范等细则不确定。</span></li>
|
||
<li class="flex"><strong class="w-16 text-red-400 flex-shrink-0">竞争风险:</strong><span>赛道涌入者众多，未来可能出现同质化竞争。</span></li>
|
||
</ul>
|
||
</div>
|
||
|
||
<div class="bento-item glass-card col-span-12 lg:col-span-6">
|
||
<h2 class="bento-item-title">综合结论与投资启示</h2>
|
||
<p class="text-gray-400 text-sm mb-3">干细胞概念已进入<strong class="text-cyan-300">基本面投资阶段</strong>，但仍处产业化极早期。投资逻辑是为确定性的临床管线和未来商业化潜力支付溢价，属<strong class="text-cyan-300">结构性精选个股机会</strong>。</p>
|
||
<p class="text-gray-400 text-sm"><strong class="text-fuchsia-300">最具价值环节：</strong>1) <strong class="text-white">下游药物研发</strong> (高弹性，关注临床后期公司)； 2) <strong class="text-white">上游“卖水人”CRO/CDMO</strong> (高确定性)。</p>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<!-- Stock Tables -->
|
||
<div x-data="{ tab: 'all' }" class="glass-card rounded-3xl p-6">
|
||
<h2 class="bento-item-title -ml-6 -mt-6 mb-6 p-6">相关概念股一览</h2>
|
||
<div role="tablist" class="tabs tabs-bordered mb-6">
|
||
<a role="tab" class="tab" :class="{ 'tab-active': tab === 'all' }" @click="tab = 'all'">全景图谱</a>
|
||
<a role="tab" class="tab" :class="{ 'tab-active': tab === 'prepare' }" @click="tab = 'prepare'">细胞制备</a>
|
||
<a role="tab" class="tab" :class="{ 'tab-active': tab === 'storage' }" @click="tab = 'storage'">细胞存储</a>
|
||
<a role="tab" class="tab" :class="{ 'tab-active': tab === 'application' }" @click="tab = 'application'">细胞应用</a>
|
||
<a role="tab" class="tab" :class="{ 'tab-active': tab === 'rise' }" @click="tab = 'rise'">涨幅异动分析</a>
|
||
</div>
|
||
|
||
<!-- All Stocks Table -->
|
||
<div x-show="tab === 'all'" class="overflow-x-auto">
|
||
<table class="table w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>股票代码</th>
|
||
<th>核心业务/关联原因</th>
|
||
<th>产业链环节</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<!-- Cells for this table will be dynamically populated -->
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
|
||
<!-- Prepare Table -->
|
||
<div x-show="tab === 'prepare'" class="overflow-x-auto">
|
||
<table class="table w-full">
|
||
<thead><tr><th>股票名称</th><th>股票代码</th><th>核心业务/关联原因</th></tr></thead>
|
||
<tbody></tbody>
|
||
</table>
|
||
</div>
|
||
|
||
<!-- Storage Table -->
|
||
<div x-show="tab === 'storage'" class="overflow-x-auto">
|
||
<table class="table w-full">
|
||
<thead><tr><th>股票名称</th><th>股票代码</th><th>核心业务/关联原因</th></tr></thead>
|
||
<tbody></tbody>
|
||
</table>
|
||
</div>
|
||
|
||
<!-- Application Table -->
|
||
<div x-show="tab === 'application'" class="overflow-x-auto">
|
||
<table class="table w-full">
|
||
<thead><tr><th>股票名称</th><th>股票代码</th><th>核心业务/关联原因</th></tr></thead>
|
||
<tbody></tbody>
|
||
</table>
|
||
</div>
|
||
|
||
<!-- Rise Analysis Table -->
|
||
<div x-show="tab === 'rise'" class="space-y-4">
|
||
<!-- Dynamic content will be inserted here -->
|
||
</div>
|
||
</div>
|
||
|
||
</main>
|
||
</div>
|
||
|
||
<script>
|
||
document.addEventListener('DOMContentLoaded', function () {
|
||
const stockData = {
|
||
"干细胞概念股（240829）": {
|
||
"2FB5F33B-B342-44F7-9F5E-366052E41369.jpg": [
|
||
{"stock": "中源协和","reason": "干细胞和免疫细胞检测制备存储。","其他标签": "细胞制备","stock_code": "600645"},
|
||
{"stock": "泰林生物","reason": "公司细胞治疗产业化装备项目为干细胞、免疫细胞等细胞治疗药物提供制备装备。","其他标签": "细胞制备","stock_code": "300813"},
|
||
{"stock": "四环生物","reason": "研发项目包含新型干细胞培养技术。","其他标签": "细胞制备"},
|
||
{"stock": "冠昊生物","reason": "研发项目包含间充质干细胞治疗技术;细胞与干细胞研发应用平台。","其他标签": "细胞制备","stock_code": "300238"},
|
||
{"stock": "开能健康","reason": "参股公司的全资子公司原天生物主营干细胞和免疫细胞的采集、制备等。","其他标签": "细胞制备","stock_code": "300272"},
|
||
{"stock": "济南高新","reason": "研发项目包含全自动细胞制备与筛选系统。","其他标签": "细胞制备"},
|
||
{"stock": "汉商集团","reason": "旗下华科生殖获得“人类干细胞制备及应用及资源保藏湖北省工程研究中心”授牌。","其他标签": "细胞存储","stock_code": "600774"},
|
||
{"stock": "南华生物","reason": "干细胞储存及技术服务、干细胞治疗研究等。","其他标签": "细胞存储"},
|
||
{"stock": "戴维医疗","reason": "参股公司希瑞科技涉及干细胞存储业务。","其他标签": "细胞存储","stock_code": "300314"},
|
||
{"stock": "南京新百","reason": "子公司齐鲁干细胞主要业务为脐带血造血干细胞检测制备、存储与提供。","其他标签": "细胞存储","stock_code": "600682"},
|
||
{"stock": "济民医疗","reason": "博鳌国际医院经营范围包括干细胞存储、细胞制备、细胞治疗。","其他标签": "细胞存储"},
|
||
{"stock": "赤天化","reason": "子公司中观生物主要开展干细胞生物技术的研究、生物制品的生产和基因技术的研究等。","其他标签": "细胞存储","stock_code": "600227"},
|
||
{"stock": "和元生物","reason": "多种免疫细胞、干细胞制备工艺；公司为多种免疫细胞治疗药物、干细胞治疗药物等客户项目提供CRO/CDMO服务。","其他标签": "细胞应用","stock_code": "688238"},
|
||
{"stock": "我武生物","reason": "公司干细胞在研项目主要是针对退行性疾病的干细胞药物研发。","其他标签": "细胞应用","stock_code": "300357"},
|
||
{"stock": "香雪制药","reason": "TCR领域的细胞免疫治疗产品和技术的研发；人体干细胞技术开发和应用。","其他标签": "细胞应用"},
|
||
{"stock": "正海生物","reason": "拓展了三个技术平台，包含干细胞技术；研发项目包含人脐带间充质干细胞。","其他标签": "细胞应用","stock_code": "300653"},
|
||
{"stock": "天士力","reason": "治疗慢性心力衰竭的人脐带间充质干细胞注射液B2278已获批临床。","其他标签": "细胞应用","stock_code": "600535"},
|
||
{"stock": "优宁维","reason": "细胞治疗领域产品为抗体及抗体相关试剂、其他生物科学试剂、仪器及耗材等。","其他标签": "细胞应用","stock_code": "301166"},
|
||
{"stock": "义翘神州","reason": "产品覆盖免疫细胞治疗和干细胞治疗领域。","其他标签": "细胞应用","stock_code": "301047"}
|
||
],
|
||
"530EE4AB-7B1F-450E-BF75-5DC426E4C631.png": [
|
||
{"stock": "中源协和","reason": "细胞制备","stock_code": "600645"},
|
||
{"stock": "开能健康","reason": "细胞制备","stock_code": "300272"},
|
||
{"stock": "四环生物","reason": "细胞制备"},
|
||
{"stock": "冠昊生物","reason": "细胞制备","stock_code": "300238"},
|
||
{"stock": "汉商集团","reason": "细胞制备","stock_code": "600774"},
|
||
{"stock": "正海生物","reason": "细胞制备","stock_code": "300653"},
|
||
{"stock": "香雪制药","reason": "细胞制备"},
|
||
{"stock": "泰林生物","reason": "细胞制备","stock_code": "300813"},
|
||
{"stock": "南京新百","reason": "细胞存储","stock_code": "600682"},
|
||
{"stock": "南华生物","reason": "细胞存储"},
|
||
{"stock": "戴维医疗","reason": "细胞存储","stock_code": "300314"},
|
||
{"stock": "冠昊生物","reason": "细胞应用","其他标签": "脑损伤","stock_code": "300238"},
|
||
{"stock": "正海生物","reason": "细胞应用","其他标签": "脑损伤","stock_code": "300653"},
|
||
{"stock": "迈普医学","reason": "细胞应用","其他标签": "脑损伤","stock_code": "301033"},
|
||
{"stock": "佰仁医疗","reason": "细胞应用","其他标签": "脑损伤","stock_code": "688198"},
|
||
{"stock": "何氏眼科","reason": "细胞应用","其他标签": "眼科","stock_code": "301103"},
|
||
{"stock": "济民健康","reason": "细胞应用","其他标签": "糖尿病","stock_code": "603222"},
|
||
{"stock": "赤天化","reason": "细胞应用","其他标签": "糖尿病","stock_code": "600227"},
|
||
{"stock": "我武生物","reason": "细胞应用","其他标签": "糖尿病","stock_code": "300357"}
|
||
]
|
||
},
|
||
"涨幅分析补充": {
|
||
"rise_analysis": [
|
||
{"stock": "九芝堂","stock_code": "000989","rise_rate": 10.06,"trade_date": "2025-07-03","reason": "核心结论: 政策催化+干细胞管线进展共振，九芝堂被资金视为“低市值创新药补涨标的”而涨停。 <br>驱动概念: 创新药+干细胞治疗+中药创新药 <br><br>个股异动解析: <br>1. 消息面： <br>（1）创新药：国家医保局7月1日印发《支持创新药高质量发展的若干措施》，明确增设“商业健康保险创新药目录”并优先纳入创新中药；九芝堂拥有缺血性脑卒中一类中药LFG（Ⅲ期将启）及YB209生物药（已获临床默示许可）。 <br>（2）干细胞治疗：7月3日午间，市场获悉九芝堂美科干细胞aPAP适应症2a期随访结束、脑卒中适应症2期入组完成，预计2026年申报附条件上市；罕见病+大病种双管线打开估值空间。 <br>（3）中药创新药优先审评：7月3日药监局发布配套细则，明确中药创新药可走优先审评通道，公司LFG项目直接受益。 <br><br>2. 基本面： <br>- 现金充裕：账面货币资金22亿元，资产负债率27%，可支撑后续临床投入。 <br>- 市值弹性：当前市值≈80亿元，在创新药板块中属小市值，资金偏好度高。"},
|
||
{"stock": "济高发展","stock_code": "600807","rise_rate": 9.92,"trade_date": "2025-11-13","reason": "核心结论: <br>政策催化“干细胞”主题+山东本地最小市值真业务沾边，短线资金集中点火封板。<br><br>驱动概念: <br>干细胞+山东国资+物业管理<br><br>个股异动解析: <br>1. 消息面： <br>（1）干细胞：板块亮点——国家卫健委11-11就《体细胞临床研究工作指引》征求意见，山东同步发布“细胞治疗突破行动方案”，自体干细胞外用药获CDE受理。 <br>- 公司2024年报将“干细胞与基因治疗”列为生命健康主业方向之一； <br>- 子公司艾克韦生物已向烟台“蓝色药谷·生命岛”细胞中试平台提供细胞培养、冻存设备与服务，实质参与中游配套。 <br><br>（2）物业管理：板块亮点——11-10中泰地产周观点提示“现房销售”政策预期，建议关注物管公司。 <br>- 公司旗下济高物业在管面积超600万㎡，为山东国资背景小型物管标的，受益政策预期。 <br><br>（3）山东国资：板块亮点——区域政策红利叠加市值管理预期。 <br>- 控股股东济南高新控股为济南高新区国资委全资，市值40亿元，具备“低位+国资+重组”标签。 <br><br>2. 基本面： <br>- 2025Q3营收7.1亿元，同比-18%；归母净利-0.6亿元，亏损收窄；资产负债率54%，账面现金7亿元，无退市风险。 <br>- 生命健康业务占比提升至28%，艾克韦生物2025H1新增细胞类订单0.21亿元，同比+120%。 <br>- 物业板块毛利率18%，高于行业平均，提供稳定现金流。"},
|
||
{"stock": "新芝生物","stock_code": "430685","rise_rate": 7.41,"trade_date": "2025-09-05","reason": "新芝生物（430685）在2025年9月5日上涨7.41%的原因可从市场情绪、概念题材、资金面及外部环境等多维度分析如下：\n\n### **一、概念题材驱动：干细胞与合成生物的热度传导**\n新芝生物属于**干细胞和合成生物概念**，这两个领域近期是市场关注的新兴方向。\n\n### **二、国产替代逻辑强化：科学仪器的进口替代空间**\n新芝生物定位为**国产科学仪器供应商**，国内中高端科学仪器长期依赖进口，国产替代需求迫切。\n\n### **三、资金面推动：北交所资金活跃与主力吸筹**\n北交所资金近期大增，新芝生物作为北交所标的可能受益于此趋势。小盘股因流通盘小、筹码集中，易被主力资金短期拉升。\n\n### **总结**\n上涨主要受**概念题材+国产替代逻辑+资金面推动+市场情绪转向小盘股**等因素驱动，当前上涨更多依赖市场情绪和资金博弈，需关注其实际业务进展及资金持续性，避免短期炒作风险。"}
|
||
]
|
||
}
|
||
};
|
||
|
||
function getUniqueStocks(data) {
|
||
const unique = new Map();
|
||
Object.values(data['干细胞概念股（240829）']).flat().forEach(stock => {
|
||
if (!unique.has(stock.stock)) {
|
||
unique.set(stock.stock, stock);
|
||
}
|
||
});
|
||
return Array.from(unique.values());
|
||
}
|
||
|
||
const allStocks = getUniqueStocks(stockData);
|
||
|
||
function createRow(stock) {
|
||
const code = stock.stock_code ? `<a href="https://valuefrontier.cn/company?scode=${stock.stock_code}" target="_blank" class="text-cyan-400 hover:underline">${stock.stock_code}</a>` : '<span class="text-gray-500">N/A</span>';
|
||
const reason = stock.reason || 'N/A';
|
||
return `<tr><td class="font-bold">${stock.stock}</td><td>${code}</td><td>${reason}</td></tr>`;
|
||
}
|
||
|
||
function createAllRow(stock) {
|
||
const code = stock.stock_code ? `<a href="https://valuefrontier.cn/company?scode=${stock.stock_code}" target="_blank" class="text-cyan-400 hover:underline">${stock.stock_code}</a>` : '<span class="text-gray-500">N/A</span>';
|
||
const reason = stock.reason || 'N/A';
|
||
let category = '未知';
|
||
if (reason.includes('制备')) category = '<span class="badge badge-outline badge-info">细胞制备</span>';
|
||
else if (reason.includes('存储') || reason.includes('储存')) category = '<span class="badge badge-outline badge-primary">细胞存储</span>';
|
||
else if (reason.includes('应用') || reason.includes('治疗')) category = '<span class="badge badge-outline badge-secondary">细胞应用</span>';
|
||
return `<tr><td class="font-bold">${stock.stock}</td><td>${code}</td><td>${reason}</td><td>${category}</td></tr>`;
|
||
}
|
||
|
||
// Populate tables
|
||
const allTableBody = document.querySelector('div[x-show="tab === \'all\'"] tbody');
|
||
allTableBody.innerHTML = allStocks.map(createAllRow).join('');
|
||
|
||
const prepareTableBody = document.querySelector('div[x-show="tab === \'prepare\'"] tbody');
|
||
prepareTableBody.innerHTML = allStocks.filter(s => (s.reason && s.reason.includes('制备')) || (s['其他标签'] && s['其他标签'].includes('制备'))).map(createRow).join('');
|
||
|
||
const storageTableBody = document.querySelector('div[x-show="tab === \'storage\'"] tbody');
|
||
storageTableBody.innerHTML = allStocks.filter(s => (s.reason && (s.reason.includes('存储') || s.reason.includes('储存'))) || (s['其他标签'] && s['其他标签'].includes('存储'))).map(createRow).join('');
|
||
|
||
const applicationTableBody = document.querySelector('div[x-show="tab === \'application\'"] tbody');
|
||
applicationTableBody.innerHTML = allStocks.filter(s => (s.reason && (s.reason.includes('应用') || s.reason.includes('治疗'))) || (s['其他标签'] && s['其他标签'].includes('应用'))).map(createRow).join('');
|
||
|
||
// Populate rise analysis
|
||
const riseContainer = document.querySelector('div[x-show="tab === \'rise\'"]');
|
||
riseContainer.innerHTML = stockData['涨幅分析补充'].rise_analysis.map(item => `
|
||
<div class="collapse collapse-arrow glass-card">
|
||
<input type="radio" name="rise-accordion" />
|
||
<div class="collapse-title text-xl font-medium orbitron">
|
||
${item.stock} (${item.stock_code}) <span class="text-lg ml-4 ${item.rise_rate > 0 ? 'text-green-400' : 'text-red-400'}">${item.rise_rate}%</span>
|
||
<span class="text-sm font-normal text-gray-400 float-right mt-1">${item.trade_date}</span>
|
||
</div>
|
||
<div class="collapse-content bg-slate-900/30">
|
||
<div class="prose prose-invert prose-sm max-w-none text-gray-400 pt-4">${item.reason}</div>
|
||
</div>
|
||
</div>
|
||
`).join('');
|
||
|
||
// ECharts
|
||
var chartDom = document.getElementById('market-size-chart');
|
||
var myChart = echarts.init(chartDom, 'dark');
|
||
var option = {
|
||
backgroundColor: 'transparent',
|
||
tooltip: {
|
||
trigger: 'axis',
|
||
axisPointer: {
|
||
type: 'shadow'
|
||
}
|
||
},
|
||
legend: {
|
||
data: ['全球市场(亿美元)', '中国市场(亿元)'],
|
||
textStyle: { color: '#ccc' }
|
||
},
|
||
grid: {
|
||
left: '3%', right: '4%', bottom: '3%', containLabel: true
|
||
},
|
||
xAxis: {
|
||
type: 'category',
|
||
data: ['2024', '2025', '2026', '2030'],
|
||
axisLine: { lineStyle: { color: 'rgba(0, 255, 255, 0.3)' } }
|
||
},
|
||
yAxis: [
|
||
{ type: 'value', name: '亿美元', axisLine: { lineStyle: { color: 'rgba(0, 255, 255, 0.3)' } }, splitLine: { lineStyle: { color: 'rgba(255,255,255,0.1)' } } },
|
||
{ type: 'value', name: '亿元', axisLine: { lineStyle: { color: 'rgba(255, 0, 255, 0.3)' } }, splitLine: { show: false } }
|
||
],
|
||
series: [
|
||
{ name: '全球市场(亿美元)', type: 'bar', data: [null, 170, null, 330], yAxisIndex: 0, itemStyle: { color: new echarts.graphic.LinearGradient(0, 0, 0, 1, [{offset: 0, color: '#00ffff'}, {offset: 1, color: '#0077ff'}]) } },
|
||
{ name: '中国市场(亿元)', type: 'line', smooth: true, data: [265, null, 325, null], yAxisIndex: 1, itemStyle: { color: '#ff00ff' } }
|
||
]
|
||
};
|
||
myChart.setOption(option);
|
||
window.addEventListener('resize', myChart.resize);
|
||
});
|
||
</script>
|
||
|
||
</body>
|
||
</html> |